ASX:PAR

3 stories mentioning ASX:PAR

Every FINWIRES story that references ASX:PAR, newest first.

Paradigm Biopharmaceuticals Completes Enrollment in Knee Osteoarthritis Trial; Shares Gain 7%

Paradigm Biopharmaceuticals (ASX:PAR) completed enrollment in a phase 3 clinical trial to evaluate its Zilosul injectable pentosan polysulfate sodium for the treatment of pain linked to knee osteoarthritis, according to a Monday filing with the Australian bourse.The company said 538 participants have started treatment in the study, surpassing the original target of 466 participants.An interim analysis of the trial remains on track for September, while top-line results are due in the first quarter of 2027, the company said.Paradigm Biopharmaceuticals shares gained 7% in recent Monday trade.

ASX:PAR

Asia49d ago

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

ASX:PAR

Asia49d ago

Paradigm Biopharmaceuticals Completes AU$14 Million Share Placement; Shares Fall 16%

Paradigm Biopharmaceuticals (ASX:PAR) completed a AU$14 million share placement to institutional and sophisticated investors, upsized from an initial target of AU$8 million due to high demand, according to a Monday filing with the Australian bourse.The company also launched a share purchase plan for eligible shareholders to generate up to an additional AU$2 million, per the filing.In the placement, the company issued about 73.7 million ordinary shares at a price of AU$0.19 each.The capital raising provides funding flexibility through the interim analysis, expected in the third quarter, of the company's phase three knee osteoarthritis trial.Shares of Paradigm Biopharmaceuticals fell nearly 16% in recent Monday trade.

ASX:PAR